Adenocarcinomas harbor targetable genomic alterations in ALK, BRAF, EGFR, and ROS1 genes, and novel treatment options such as KRAS Gly12Cys, MET, NTRK, and RET inhibitors, and possibly ERBB2 guided therapies are broadening the clinical repertoire [3], [4], [5]. The gene discussed is ROS1; the disease is adenocarcinoma.